Subsequent Event (Tables)

6 Months Ended

Jun. 30, 2013

Melphalan license [Member]

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows ($ in 000’s):

In-process research and development—Captisol-enabled^®, propylene glycol-free melphalan rights $  7,700

Talon Therapeutics, Inc. [Member]

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The following table summarizes the fair value of the net assets acquired as of July 17, 2013 ($ in 000’s):

Cash and equivalents	$	131
Inventory		611
Prepaid expenses and other current assets		602
Property and equipment		30
Identifiable intangible assets		46,300
Goodwill		20,606
Total assets acquired		68,280
Accounts payable & accrued liabilities		6,870
Contingent value rights		6,500
Deferred tax liability		17,300
Total liabilities assumed		30,670
Net assets acquired	$	37,610

Weighted-Average Amortization Period for such Intangible Assets Acquired

The acquired Marqibo intangible assets consisted of developed technology and in-process research and development for the treatment of acute lymphoblastic leukemia (“ALL”) and non-Hodgkin’s lymphoma (“NHL”) as follows in the table below ($ in 000’s):

	Value of Intangible Assets Acquired		Weighted-Average Amortization Period
Developed technology—Marqibo for ALL	$	27,800		(1)
In-process research and development—Marqibo for NHL		18,500		(1)
Total identifiable intangible assets	$	46,300

(1) Acquired in-process research and development (“IPR&D”) is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated R&D effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. Intangible IPR&D is not amortized during the period that it is considered indefinite-lived but rather tested for impairment.